2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).
Tim G. Larson, MD, oncologist, Minnesota Oncology, discusses ongoing trials in colorectal cancer (CRC).
The BEACON trial is looking at patients with BRAF mutations, which is a small subset of patients with CRC who have a poor prognosis and do not respond to the standard treatments. This trial is offering these patients promising therapies, says Larson.
A different phase III trial is examining the effectiveness of napabucasin (BBI-608), an oral cancer stem cell inhibitor, in the second-line setting.